Literature DB >> 30300214

Predictors of Antiretroviral Adherence Self-efficacy Among People Living With HIV/AIDS in a Canadian Setting.

William K Lee1, Michael John S Milloy1,2, Ekaterina Nosova1, John Walsh3, Thomas Kerr1,2.   

Abstract

BACKGROUND: Suboptimal adherence to antiretroviral therapy (ART) among people living with HIV/AIDS (PLWHA) who use illicit drugs remains an ongoing health concern. Although health outcomes associated with adherence self-efficacy have been well-documented, there is dearth research exploring the predictors of this construct. This study sought to identify possible determinants of adherence self-efficacy among a cohort of PLWHA who use illicit drugs.
METHODS: From December 2004 to May 2014, we collected data from the AIDS Care Cohort to evaluate Exposure to Survival Services, a prospective cohort of adult PLWHA who use illicit drugs in Vancouver, Canada. We used multivariate generalized estimating equation analyses to identify longitudinal factors independently associated with higher adherence self-efficacy.
RESULTS: Among 742 participants, 493 (66.4%) identified as male and 406 (54.7%) reported white ancestry. In multivariate generalized estimating equation analysis, older age at ART initiation (adjusted odds ratio [AOR] = 1.02, 95% confidence interval [CI]: 1.00 to 1.03) and recent year of baseline interview (AOR = 1.08, 95% CI: 1.05 to 1.11) were independently associated with higher adherence self-efficacy, whereas homelessness (AOR = 0.78, 95% CI: 0.65 to 0.94), ≥daily crack smoking (AOR = 0.81, 95% CI: 0.68 to 0.96), experienced violence (AOR = 0.82, 95% CI: 0.69 to 0.98), and childhood abuse (AOR = 0.75, 95% CI: 0.60 to 0.92) were negatively associated.
CONCLUSIONS: These findings highlight the potential role that personal and contextual factors can play in predicting levels of ART adherence self-efficacy. Future research should seek to identify and validate strategies to optimize adherence self-efficacy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30300214      PMCID: PMC6347383          DOI: 10.1097/QAI.0000000000001878

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  44 in total

1.  Factors related to self-efficacy for use of condoms and birth control among women at risk for HIV infection.

Authors:  J L Lauby; S Semaan; A O'Connell; B Person; A Vogel
Journal:  Women Health       Date:  2001

2.  Effects of traumatic events, social support, and self-efficacy on adolescents' self-health assessments.

Authors:  K H Cheever; S B Hardin
Journal:  West J Nurs Res       Date:  1999-10       Impact factor: 1.967

3.  Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change.

Authors:  Michael P Bogenschutz; J Scott Tonigan; William R Miller
Journal:  J Stud Alcohol       Date:  2006-07

4.  Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model.

Authors:  Mallory O Johnson; Margaret A Chesney; Rise B Goldstein; Robert H Remien; Sheryl Catz; Cheryl Gore-Felton; Edwin Charlebois; Stephen F Morin
Journal:  AIDS Patient Care STDS       Date:  2006-04       Impact factor: 5.078

5.  Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting.

Authors:  Jane Loh; Mary Clare Kennedy; Evan Wood; Thomas Kerr; Brandon Marshall; Surita Parashar; Julio Montaner; M-J Milloy
Journal:  AIDS Care       Date:  2016-06-01

6.  Social learning theory and the Health Belief Model.

Authors:  I M Rosenstock; V J Strecher; M H Becker
Journal:  Health Educ Q       Date:  1988

7.  The adherence gap: a longitudinal examination of men's and women's antiretroviral therapy adherence in British Columbia, 2000-2014.

Authors:  Cathy M Puskas; Angela Kaida; Cari L Miller; Wendy Zhang; Benita Yip; Neora Pick; Julio S G Montaner; Robert S Hogg
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

8.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

9.  The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.

Authors:  Will Small; Evan Wood; Glenn Betteridge; Julio Montaner; Thomas Kerr
Journal:  AIDS Care       Date:  2009-06

10.  Atriplatrade mark - HIV therapy in one pill.

Authors:  Boris Julg; Johannes R Bogner
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

View more
  3 in total

Review 1.  ART Adherence Among Men Who Have Sex with Men Living with HIV: Key Challenges and Opportunities.

Authors:  Katherine G Quinn; Dexter R Voisin
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

2.  Non-fatal stimulant overdose among homeless and unstably housed women in San Francisco, California.

Authors:  Thibaut Davy-Mendez; Eric Vittinghoff; Samantha E Dilworth; Leslie W Suen; Carl Braun; Phillip O Coffin; Derek D Satre; Elise D Riley
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

3.  Risk Factors for Suboptimal Adherence Identified by Patient-Reported Outcomes Assessments in Routine HIV Care at 2 North American Clinics.

Authors:  Duncan Short; Xueqi Wang; Shivali Suri; Thomas K Hsu; Bryn Jones; Rob J Fredericksen; Heidi M Crane; Alexandra Musten; Jean Bacon; Yongwei Wang; Kevin A Gough; Moti Ramgopal; Jeff Berry; William B Lober
Journal:  Patient Prefer Adherence       Date:  2022-09-05       Impact factor: 2.314

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.